Affiliation:
1. National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences
2. Guang’anmen Hospital, China Academy of Chinese Medical Sciences
3. Cardiovascular Center, Beijing Tongren Hospital, Capital Medical University
Abstract
Abstract
Background
Intermediate coronary lesion (ICL) is a critical stage affecting coronary artery disease’s progression and prognosis and may quickly progress to acute coronary syndrome. However, percutaneous coronary intervention therapy and conventional drug therapy have certain limitations. Qing-Xin-Jie-Yu Granules (QXJYG), a Chinese herbal prescription with a pre-research basis, has the potential to be a complementary treatment for ICL. Previous studies have shown that QXJYG combined with conventional drug therapy could alleviate angina symptoms and reduce the incidence of composite ‘hard’ endpoint in treating stable coronary artery disease. However, for ICL, the effect of this prescription on the degree of coronary stenosis, plaque stability, and long-term efficacy remains unclear. Therefore, we designed this study to evaluate the efficacy and safety of QXJYG in patients with ICL.
Methods
This is a multi-center, block-randomized, double-blinded, placebo-controlled trial. One hundred and twenty participants with ICL will be randomly assigned to two groups in a 1:1 ratio. Based on conventional intervention, the participants of the treatment group will receive QXJYG orally, and the participants of the control group will receive placebo for six successive months. The primary outcomes involve the degree of coronary stenosis, including the percentage of diameter stenosis and the percentage of area stenosis measured by coronary CT angiography. The secondary outcomes involve coronary artery calcification score, Gensini score, CT-fractional flow reserve, angina symptom score, traditional Chinese medicine syndrome score, blood lipids, inflammatory factors, carotid artery ultrasound parameters, and major adverse cardiovascular events. Safety will be assessed by adverse events and laboratory examinations. Measurements will be performed at baseline (visit 1), months 2 (visit 2), months 4 (visit 3), months 6 (visit 4), and months 12 (visit 5).
Discussion
The results of this trial will verify the efficacy and safety of QXJYG in treating ICL, thus adding to the existing knowledge for resolving the problem in ICL.
Trial registration:
This trial is registered at the Chinese Clinical Trial Registry (www.chictr.org.cn). Registration number: ChiCTR2200059262. Register date: April 27, 2022.
Publisher
Research Square Platform LLC
Reference55 articles.
1. World Health Organization. Global health estimates: Leading causes of death Geneva: World Health Organization. ; 2020 [Available from: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death.
2. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019;GBD 2019 Diseases and Injuries Collaborators;Lancet,2020
3. Report on Cardiovascular Health and Diseases Burden in China: an Updated Summary of 2020;The Writing Committee of the Report on Cardiovascular Health and Diseases in China;Chin Circulation J,2021
4. STS 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons;Patel MR;J Thorac Cardiovasc Surg,2019
5. Angiographic progression of coronary artery disease and the development of myocardial infarction;Ambrose JA;J Am Coll Cardiol,1988